AbbVie Nears $11B Deal to Buy Apogee Therapeutics
AbbVie (ABBV) is close to acquiring Apogee Therapeutics (APGE) for approximately $11 billion, according to a Financial Times report. Apogee shares surged on the news.
Key Numbers
AbbVie is nearing a deal to acquire Apogee Therapeutics, a developer of inflammatory disease drugs, for about $11 billion, according to a Financial Times report. Apogee shares soared on the news.
Deal Details
- Value: Approximately $11 billion.
- Buyer: AbbVie (ticker: ABBV).
- Target: Apogee Therapeutics (ticker: APGE).
- Source: Financial Times, citing sources familiar with the matter.
- Status: Talks are advanced; no official announcement yet.
Rationale
AbbVie aims to strengthen its pipeline in inflammatory diseases, a key therapeutic area. Apogee has a promising late-stage drug candidate for asthma and atopic dermatitis, which could help offset revenue loss from AbbVie's patent expirations.
Regulatory Challenges
The deal will likely face antitrust review in the U.S. and Europe. However, given limited product overlap, it is expected to pass without major hurdles.
Impact on Stocks
- Apogee (APGE): Shares surged sharply and may rise further if the deal is confirmed at a premium.
- AbbVie (ABBV): The stock may face slight pressure due to the acquisition cost, but long-term impact is positive if the deal enhances pipeline.
Frequently Asked Questions
Found this useful? Share it